Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.
Expert Opin Pharmacother
; 19(4): 387-395, 2018 03.
Article
em En
| MEDLINE
| ID: mdl-29397790
ABSTRACT
INTRODUCTION:
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central nervous system affecting both white matter and grey matter in the earliest phases of its course. The crucial role of neurodegeneration in disability progression in MS, regardless of white matter damage, has been confirmed by several imaging and neuropathological studies. Fingolimod is an effective immunomodulator of the sphingosine 1-phosphate receptor, approved in relapsing remitting MS and able to cross the blood-brain barrier and to slow disability progression and brain volume loss. However, it remains unclear whether this neuroprotective action is due to a peripheral anti-inflammatory effect and/or to a direct effect on neuronal cells. AREAS COVERED In this review, the authors summarize the published preclinical and clinical studies on the effect of Fingolimod in limiting the focal and diffuse grey matter damage in MS. EXPERT OPINION Fingolimod might have a significant neuroprotective effect on relapsing remitting MS based on its modulatory effect on oligodendroglial cells and astrocytes, and on its direct effect on cortical neurons. Future clinical studies including measures of grey matter damage are required to confirm in vivo such neuroprotective effect.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Fármacos Neuroprotetores
/
Cloridrato de Fingolimode
/
Imunossupressores
/
Esclerose Múltipla
Tipo de estudo:
Risk_factors_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Pharmacother
Assunto da revista:
FARMACOLOGIA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Itália